Skip to main content

POBLACIONES SUBCLONALES DE LMA Y CELULAS MADRE LEUCEMICAS IDENTIFICADAS MEDIANTE SECUENCIACION DE ARN DE UNA SOLA CELULA Y CITOMETRIA DE FLUJO MULTIPARAMETRICA: IMPACTO EN LA RESPUESTA AL TRATAMIENTO

PI20/01621

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Arnan, Montserrat
  • Pomares, Helena
  • Alonso, Ester
  • Tormo, Mar|||0000-0001-9622-1649
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Sampol, Antonia|||0000-0001-7465-6203
  • Coll, Rosa|||0000-0003-0560-1254
  • Salamero, Olga|||0000-0003-3237-0025
  • Cervera, Marta
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Garcia-Avila, Sara|||0000-0002-9293-2029
  • Bargay, Joan|||0000-0002-6739-3916
  • Ortin, Xavier
  • Iranzo, Eva
  • Guijarro, Francesca|||0000-0001-6376-0929
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Sierra, Jorge|||0000-0002-7966-0356
Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will perform poorly, and in whom alternative approaches deserve investigation. We analyzed 1034 fit adults ≤70 years intensively treated between 2012 and 2022 in the CETLAM group. Young adults ( ≤ 60 years) presented higher remission rates and improved survival than older adults above that age (CR 79% vs. 73%; p = 0.03 and 4-yr OS 53% vs. 33%; p < 0.001). Remission and survival outcomes varied among different genetic subsets. An especially adverse genetic group included complex, monosomal karyotype, TP53 alterations (deleted/mutated), and MECOMr. Transplant feasibility in this very adverse risk group was low, and OS and EFS at 4 years were 14% and 12%, in contrast to 70% and 57% in the favorable group and 38% and 32% in all other patients. We integrated clinical and genetic data into the Intensive Chemotherapy Score for AML (ICSA) with 6-risk categories with significantly different remission rates and OS, validated in another cohort of 581 AML patients from a previous CETLAM protocol. In summary, we identified groups of fit patients that benefit differently from an intensive approach which may be helpful in future treatment decisions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model

  • Garcia León, Annabel|||0000-0003-3007-9306
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Rueda, Ariana|||0000-0001-7588-9279
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sierra, Jorge|||0000-0002-7966-0356
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Acute myeloid leukemia (AML) presents major clinical challenges due to chemoresistance and high relapse rates, primarily driven by therapy-resistant leukemic stem cells (LSCs) within the bone marrow. To address this issue, we developed T22-HSNBT-H6-MMAE, a novel humanized nanoconjugate designed to target CXCR4 cells while delivering the cytotoxic payload monomethyl auristatin E (MMAE). CXCR4 signaling pathway plays a critical role in LSC survival by preserving stem-like properties and activating protective mechanisms that promote treatment resistance. Moreover, CXCR4 is overexpressed in approximately 50 % of AML patients and is associated with poor prognosis and high relapse rates. We evaluated the therapeutic potential of T22-HSNBT-H6-MMAE using in vitro assays with AML cell lines and primary patient samples, as well as in vivo studies in a disseminated AML mouse model. Our results demonstrated that T22-HSNBT-H6-MMAE exerts a CXCR4-dependent cytotoxic effect through mitotic catastrophe and apoptosis induction in CXCR4 AML cell lines. In vivo evaluation in a disseminated CXCR4 AML mouse model showed potent antineoplastic activity, with complete suppression of leukemic dissemination and significantly prolonged survival, all without systemic toxicity. Notably, the nanoconjugate remained effective even in models with extensive bone marrow involvement and exhibited activity against diverse patient-derived CXCR4 AML blasts, while sparing healthy donor bone marrow and peripheral blood mononuclear cells (PBMCs) from significant toxicity. Collectively, these findings highlight T22-HSNBT-H6-MMAE as a promising therapeutic candidate for a broad range of AML patients, offering selective antineoplastic activity against CXCR4 leukemic cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Bataller, Alex|||0000-0002-6085-2745
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Arnan, Montserrat
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Coll, Rosa|||0000-0003-0560-1254
  • Tormo, Mar|||0000-0001-9622-1649
  • Sampol, Antonia|||0000-0001-7465-6203
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Salamero, Olga|||0000-0003-3237-0025
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Bargay, Joan|||0000-0002-6739-3916
  • Aljarilla, Alba
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Sierra, Jorge|||0000-0002-7966-0356
  • Pratcorona, Marta|||0000-0001-6375-596X
The negative prognostic impact of internal tandem duplication of FLT3 (FLT3- ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML- NPM1) is restricted to those with a higher FLT3 -ITD allelic ratio (FLT3 high ; ≥0.5) and considered negligible in those with a wild-type (FLT3 WT)/low ITD ratio (FLT3 low). Because the comutation of DNMT3A (DNMT3A mut) has been suggested to negatively influence prognosis in AML- NPM1, we analyzed the impact of DNMT3A mut in FLT3 -ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML- NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3A mut status did not have a prognostic impact, with comparable overall survival (P =.2). Prognostic stratification established by FLT3 -ITD (FLT3 WT = FLT3 low.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia, validation in a risk-adapted protocol

  • Bataller, Alex|||0000-0002-6085-2745
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Guijarro, Francesca|||0000-0001-6376-0929
  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Arnan, Montserrat
  • Tormo, Mar|||0000-0001-9622-1649
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Queipo de Llano, María Paz
  • Coll, Rosa|||0000-0003-0560-1254
  • Gallardo, David|||0000-0003-1615-4592
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Salamero, Olga|||0000-0003-3237-0025
  • Sampol, Antonia|||0000-0001-7465-6203
  • Merchan, Brayan M.|||0000-0002-6733-6006
  • Bargay, Joan|||0000-0002-6739-3916
  • Castaño-Díez, Sandra|||0000-0001-9044-4665
  • Esteban Corredera, Daniel|||0000-0001-8897-3170
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Rivero, Andrea|||0000-0002-4233-5031
  • Mozas, Pablo|||0000-0001-9528-4971
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Costa, Dolors|||0000-0002-8276-3292
  • Rozman, Maria|||0000-0002-2641-1110
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Colomer, Dolors|||0000-0001-7486-8484
  • Brunet, Salut|||0000-0003-0491-1672
  • Sierra, Jorge|||0000-0002-7966-0356
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to assess the prognosis and postremission therapy of patients. However, they have been retrospectively validated in few studies with patients included in different treatment protocols. We analyzed 861 patients included in the Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation for patients allocated to the ELN 2017 favorable-risk group, whereas it recommends allogeneic stem cell transplantation (alloSCT) as a postremission strategy for the ELN 2017 intermediate- and adverse-risk groups. We retrospectively classified patients according to the ELN 2017, with 327 (48%), 109 (16%), and 245 (36%) patients allocated to the favorable-, intermediate-, and adverse-risk group, respectively. The 2- and 5-year overall survival (OS) rates were 77% and 70% for favorable-risk patients, 52% and 46% for intermediate-risk patients, and 33% and 23% for adverse-risk patients, respectively. Furthermore, we identified a subgroup of patients within the adverse group (inv(3)/t(3;3), complex karyotype, and/or TP53 mutation/17p abnormality) with a particularly poor outcome, with a 2-year OS of 15%. Our study validates the ELN 2017 risk stratification in a large cohort of patients treated with an ELN-2017 risk-adapted protocol based on alloSCT after remission for nonfavorable ELN subgroups and identifies a genetic subset with a very poor outcome that warrants investigation of novel strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice

  • Falgàs, Aïda|||0000-0002-5040-2265
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Aragó, Marc|||0000-0002-9645-0131
  • Álamo, Patricia|||0000-0003-0510-5701
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
High rates of relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients and life-threatening side effects associated with immunochemotherapy make an urgent need to develop new therapies for DLBCL patients. Immunotoxins seem very potent anticancer therapies but their use is limited because of their high toxicity. Accordingly, the self-assembling polypeptidic nanoparticle, T22-DITOX-H6, incorporating the diphtheria toxin and targeted to CXCR4 receptor, which is overexpressed in DLBCL cells, could offer a new strategy to selectively eliminate CXCR4 DLBCL cells without adverse effects. In these terms, our work demonstrated that T22-DITOX-H6 showed high specific cytotoxicity towards CXCR4 DLBCL cells at the low nanomolar range, which was dependent on caspase-3 cleavage, PARP activation and an increase of cells in early/late apoptosis. Repeated nanoparticle administration induced antineoplastic effect, in vivo and ex vivo, in a disseminated immunocompromised mouse model generated by intravenous injection of human luminescent CXCR4 DLBCL cells. Moreover, T22-DITOX-H6 inhibited tumor growth in a subcutaneous immunocompetent mouse model bearing mouse CXCR4 lymphoma cells in the absence of alterations in the hemogram, liver or kidney injury markers or on-target or off-target organ histology. Thus, T22-DITOX-H6 demonstrates a selective cytotoxicity towards CXCR4 DLBCL cells without the induction of toxicity in non-lymphoma infiltrated organs nor hematologic toxicity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Survival improvement of patients with FLT3 mutated acute myeloid leukemia, results from a prospective 9 years cohort

  • Oñate, Guadalupe|||0000-0003-2180-2371
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Artigas-Baleri, Alícia|||0000-0003-0486-268X
  • Bataller, Alex|||0000-0002-6085-2745
  • Tormo, Mar|||0000-0001-9622-1649
  • Arnan, Montserrat
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Coll, Rosa|||0000-0003-0560-1254
  • Salamero, Olga|||0000-0003-3237-0025
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Sampol, Antonia|||0000-0001-7465-6203
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Cervera, Marta
  • Garcia-Avila, Sara|||0000-0002-9293-2029
  • Bargay, Joan|||0000-0002-6739-3916
  • Ortín, Xavier
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Sierra, Jorge|||0000-0002-7966-0356
Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3 mut). We analyzed the impact of midostaurin in 227 FLT3 mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divided into an early (2012-2015) and late (2016-2020) cohorts. They were uniformly treated except for the addition of midostaurin in 71% of late group patients. No differences were observed in response rates or the number of allotransplants between groups. Outcome was improved in the late period: 2-year relapse incidence decreased from 42% vs 29% in early vs late group (p = 0.024) and 2-year overall survival (OS) improved from 47% vs 61% (p = 0.042), respectively. The effect of midostaurin was evident in NPM1 mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011) and mitigated FLT3 -ITD allelic ratio prognostic value: 2-yr OS with midostaurin was 85% and 58% in low and high ratio patients (p = 0.049) vs 67% and 39% in naive patients (p = 0.005). In the wild-type NPM1 subset (n = 75), we did not observe significant differences between both study periods. In conclusion, this study highlights the improved outcome of FLT3 mut AML fit patients with the incorporation of midostaurin.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo

  • Núñez, Yáiza|||0000-0001-7268-2125
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Despite advances in the development of targeted therapies for acute myeloid leukemia (AML), most patients relapse. For that reason, it is still necessary to develop novel therapies that improve treatment effectiveness and overcome drug resistance. We developed T22-PE24-H6, a protein nanoparticle that contains the exotoxin A from the bacterium Pseudomonas aeruginosa and is able to specifically deliver this cytotoxic domain to CXCR4 + leukemic cells. Next, we evaluated the selective delivery and antitumor activity of T22-PE24-H6 in CXCR4 + AML cell lines and BM samples from AML patients. Moreover, we assessed the in vivo antitumor effect of this nanotoxin in a disseminated mouse model generated from CXCR4 + AML cells. T22-PE24-H6 showed a potent, CXCR4-dependent antineoplastic effect in vitro in the MONO-MAC-6 AML cell line. In addition, mice treated with nanotoxins in daily doses reduced the dissemination of CXCR4 + AML cells compared to buffer-treated mice, as shown by the significant decrease in BLI signaling. Furthermore, we did not observe any sign of toxicity or changes in mouse body weight, biochemical parameters, or histopathology in normal tissues. Finally, T22-PE24-H6 exhibited a significant inhibition of cell viability in CXCR4 high AML patient samples but showed no activity in CXCR4 low samples. These data strongly support the use of T22-PE24-H6 therapy to benefit high-CXCR4-expressing AML patients.